Researchers have uncovered how specific patterns in brain activity can predict an individual's sensitivity to pain, expanding opportunities for improved pain management strategies.

NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 preliminary results amid a weak SCS market.

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

Nevro Corp. , a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its preliminary, unaudited fourth-quarter and ...